Clinical trials: Measles
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
This phase I trial investigates the side effects and best dose of using a modified measles virus, MV-s-NAP, in treating patients with invasive breast cancer that has spread to other places in the body (metastatic).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04521764
- Testing
- Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Mayo Clinic
Measles
Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Measles is a vaccine-preventable disease, which can be life-threatening in immunosuppressed children. Currently, measles vaccine is not recommended in pediatric orthotopic liver transplant recipients, because it is a…
- Trial name
- MMRinOLT (NCT01770119)
- Testing
- MMR vaccination
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Klara M. Pósfay Barbe
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles
Barriers and Facilitators to MMR Vaccination Among Healthcare Workers
Measles is a highly contagious disease which can result in severe complications in some patients. Healthcare workers have a higher risk of getting measles than the general population because of their increased risk of exposure…
- Trial name
- BFMMRHCW (NCT06456788)
- Testing
- MMR vaccination
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- King's College London
Multiple Sclerosis, Hypogammaglobulinemia
Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis
B cells are considered major contributors to multiple sclerosis (MS) pathogenesis, a role that has taken on renewed importance with the advent of B-cell-depleting therapies.
- Trial name
- NCT04283747
- Testing
- Serum immunoglobulin titer
- Where
- Iran
- Volunteers
- 170 people
- Sponsor
- Mazandaran University of Medical Sciences
Immunotoxicity, Vaccine
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.
- Trial name
- NCT05161845
- Testing
- Measles, Mumps and Rubella Combined Vaccine, Live
- Where
- China
- Volunteers
- 1,068 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Mumps
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine, live (MMRV).
- Trial name
- NCT04364399
- Testing
- Mumps vaccine, measles, mumps and rubella combined vaccine, live
- Where
- China
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Pregnancy
Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies
The aim of the research is to study humoral and cellular immunity in pregnant women for who the level of rubella virus antibodies is weakly positive, equivocal or negative with the usual laboratory technique.
- Trial name
- ImmRubVac (NCT02934295)
- Testing
- Determination of Anti-Rubella Antibody, E1
- Where
- 2 sites in France
- Volunteers
- 192 people
- Sponsor
- Hopital Foch
Measles-Mumps-Rubella
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when…
- Trial name
- NCT01621802
- Testing
- Priorix, M-M-R II, Kinrix
- Where
- 67 sites in United States, South Korea and 1 more
- Volunteers
- 4,011 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles Vaccination, Oral Polio Vaccine
Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children
The world is set on eradicating measles and polio infections in the coming decade. Once both infections are under control, campaigns with measles and oral polio vaccines will be phased out.
- Conditions
- Measles Vaccination, Oral Polio Vaccine, Non-specific/Heterologous Effects of Vaccines, Mortality
- Trial name
- RE-CAMP (NCT03460002)
- Testing
- Measles vaccine, Oral polio vaccine
- Where
- Guinea-Bissau
- Volunteers
- 28,612 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and…
- Conditions
- Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
- Trial name
- NCT02962167
- Testing
- Modified Measles Virus, Modified Measles Virus Lumbar Puncture
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sabine Mueller, MD, PhD
Measles Vaccine
Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
Background: All observational studies and a few randomised controlled trials (RCT) suggest that early measles vaccine (MV), in particular an early two-dose strategy, has a much better effect on overall mortality than later MV.
- Trial name
- NCT01668745
- Testing
- Early measles vaccine
- Where
- Burkina Faso
- Volunteers
- 4,559 people
- Sponsor
- Bandim Health Project
Measles, Mumps
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on…
- Conditions
- Measles, Mumps, Rubella, Hepatitis A
- Trial name
- NCT00313950
- Testing
- Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles Vaccination
Predictors of Measles Vaccine Hesitancy in New York State
Under-immunization rates for childhood immunizations in the United States range from 8-20%. Previous studies have demonstrated that pediatric patients are most likely to be under-immunized for seasonal immunizations.
- Trial name
- NCT07373093
- Testing
- Survey
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Albany Medical College
Measles; Mumps; Rubella; Chickenpox, Measles
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
- Trial name
- NCT05630846
- Testing
- Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine
- Where
- 47 sites in United States, Colombia and 3 more
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
The primary objective of the study was to determine if intranasally administered influenza virus vaccine, CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles…
- Trial name
- NCT00192166
- Testing
- CAIV-T
- Where
- Singapore
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Measles
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).
- Trial name
- NCT00109278
- Testing
- V205C, measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mumps, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Since measles-mumps-rubella (MMR) and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life, a combined measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine…
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00352898
- Testing
- MeMuRu-OKA (study vac), MMR, Varicella vacc (control)
- Where
- 6 sites in Canada, Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV
MMR Vaccination Among HIV-infected Adults
This is a prevalence study of protective antibodies to measles, mumps, and rubella (MMR) in HIV-infected adults and HIV-uninfected controls.
- Trial name
- NCT02724852
- Testing
- 0.5 ml of MMR vaccine
- Where
- Thailand
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline